阿戈美拉汀与度洛西汀治疗抑郁症的效果和不良反应比较

Comparison of the effect and adverse reactions of agomelatine and duloxetine in the treatment of depression

目的 比较阿戈美拉汀与度洛西汀治疗抑郁症的效果以及不良反应。方法 78例抑郁症患者,按照随机数字表法分成对照组和研究组,各39例。对照组应用度洛西汀治疗,研究组应用阿戈美拉汀治疗。比较两组治疗前后的汉密尔顿抑郁量表(HAMD)评分、匹茨堡睡眠质量指数(PSQI)评分以及不良反应发生情况。结果 治疗后,两组患者的HAMD评分均较本组治疗前降低,且研究组患者的HAMD评分(14.21±3.28)分低于对照组的(22.92±3.15)分,差异具有统计学意义(P<0.05)。治疗后,研究组患者的入睡时间、睡眠时间、睡眠效率、睡眠障碍、睡眠质量、催眠药物、日间功能障碍评分均低于对照组,但差异无统计学意义(P>0.05);研究组患者治疗后的PSQI总分(12.67±1.24)分低于对照组的(13.70±1.53)分,差异有统计学意义(P<0.05)。研究组不良反应发生率为12.82%,与对照组的17.95%比较,差异无统计学意义(P>0.05)。结论 阿戈美拉汀和度洛西汀均为治疗抑郁症的药物,且均有一定的疗效,但阿戈美拉汀治的疗效果更加突出,能明显改善患者的睡眠质量,且不良反应相对比较少,因此在抑郁症治疗中可以作进一步的推荐。

Objective To compare the effect and adverse reactions of agomelatine and duloxetine in the treatment of depression. Methods A total of 78 patients with depression were divided into control group and research group according to random numerical table, with 39 patients in each group. The control group was treated with duloxetine, and the research group was treated with agomelatine. The Hamilton Depression Scale(HAMD) score and Pittsburgh Sleep Quality Index(PSQI) score before and after treatment, and occurrence of adverse reactions were compared between the two groups. Results After treatment, the HAMD scores in both groups were lower than those before treatment in this group, and the HAMD score(14.21±3.28) points in the research group was lower than(22.92±3.15) points in the control group, and the differences were statistically significant(P<0.05). After treatment, the scores of falling asleep time, sleep time, sleep efficiency, sleep disorder,sleep quality, hypnotic drugs and daytime dysfunction in the research group were lower than those in the control group, but the differences were not statistically significant(P>0.05). The total PSQI score(12.67±1.24) points in the research group after treatment was lower than(13.70±1.53) points in the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the research group was 12.82%, which had no statistically significant difference compared with 17.95% in the control group(P>0.05). Conclusion Both agomelatine and duloxetine are drugs for the treatment of depression, and both have certain efficacy. However, the efficacy of agomelatine treatment is more prominent, and can significantly improve the sleep quality of patients with relatively few adverse reactions, which can be further recommended in the treatment of depression.